Abstract
RNA interference continues to offer significant promise for a host of
therapeutic treatments. Potentially any disease-causing gene, cell type or
tissue can be targeted with RNAi, including those not ' druggable' with small
molecules or protein-based therapies. Pharma companies are increasingly
investing in siRNA optimization or examining siRNA alternatives, in addition
to staking out proprietary positions in lipid-based, nanotransporter-based and
alternative delivery technologies. The development and licensing of such
platforms will become crucial for developers over the coming years. ' The
Future of RNAi Therapeutics: Drug pipelines and prospects' is a new report
published by Business Insights that provides an in-depth assessment of recent
progress and future opportunities for RNAi players in major therapeutic areas
including infectious diseases, cancer, inflammation/immune dysfunction, CNS
disorders and cardiology/metabolism. The latest trends in RNAi therapeutics
are examined, focusing on the main areas of clinical need, general/proprietary
technologies and company pipelines, and the activities and strategies of 37
RNAi-based developers are profiled. This report also provides forecasts for
market growth to 2012 across major RNAi market segments. Identify the
developmental status of key RNAi agents, review the latest advances in RNAi
technologies and assess the competitive landscape with this report' s analysis
of 37 companies across major therapeutic areas.
| 
View Cart
